genmab
adc
therapeutics
announce
amended
agreement
camidanlumab
tesirine
cami
media
release
copenhagen
denmark
lausanne
switzerland
october
adc
therapeutics
continue
development
commercialization
cami
genmab
receive
tiered
royalty
genmab
nasdaq
gmab
adc
therapeutics
sa
nyse
adct
today
announced
executed
amended
agreement
adc
therapeutics
continue
development
commercialization
camidanlumab
tesirine
cami
parties
first
entered
collaboration
license
agreement
june
development
cami
antibody
drug
conjugate
adc
combines
genmab
antibody
targeting
adc
therapeutics
highly
potent
pyrrolobenzodiazepine
pbd
warhead
technology
terms
agreement
parties
determine
path
forward
continued
development
commercialization
cami
upon
completion
phase
b
clinical
trial
adc
therapeutics
previously
announced
cami
achieved
overall
response
rate
including
complete
response
rate
hodgkin
lymphoma
patients
trial
received
median
five
prior
lines
therapy
cami
currently
evaluated
pivotal
phase
clinical
trial
intended
support
submission
biologics
license
application
bla
food
drug
administration
fda
trial
percent
enrolled
adc
therapeutics
anticipates
reporting
interim
results
first
half
relationship
adc
therapeutics
team
believe
ideal
partner
ongoing
development
potential
commercialization
cami
said
jan
van
de
winkel
chief
executive
officer
genmab
look
forward
continued
advancement
delighted
reached
agreement
genmab
allow
adc
therapeutics
leverage
commercial
organization
building
lead
program
loncastuximab
tesirine
lonca
lymphoma
said
chris
martin
chief
executive
officer
adc
therapeutics
started
collaborating
genmab
development
cami
adc
therapeutics
startup
since
time
team
grown
significantly
encompass
aspects
adc
research
development
commercial
organization
including
hematology
sales
force
establishing
position
us
strongly
commercialization
cami
terms
amended
restated
license
agreement
parties
agreed
eliminate
defined
divestment
process
agreed
envisaged
among
things
offering
opportunity
third
parties
continue
development
commercialization
cami
parties
also
agreed
among
things
genmab
convert
economic
interest
cami
tiered
royalty
net
sales
camidanlumab
tesirine
cami
camidanlumab
tesirine
cami
formerly
antibody
drug
conjugate
adc
comprised
human
monoclonal
antibody
binds
licensed
genmab
conjugated
pyrrolobenzodiazepine
pbd
dimer
payload
tesirine
bound
cell
internalized
cell
enzymes
release
warhead
killing
cell
applies
tumor
cells
also
tregs
release
pbd
warhead
may
also
cause
bystander
killing
neighboring
tumor
cells
pbds
also
shown
induce
immunogenic
cell
death
properties
cami
may
enhance
activity
cami
evaluated
pivotal
phase
clinical
trial
patients
relapsed
refractory
hodgkin
lymphoma
hl
well
phase
clinical
trial
patients
relapsed
refractory
hl
lymphoma
phase
clinical
trial
monotherapy
planned
arm
combination
pembrolizumab
solid
tumors
genmab
genmab
publicly
traded
international
biotechnology
company
specializing
creation
development
differentiated
antibody
therapeutics
treatment
cancer
founded
company
creator
following
approved
antibodies
daratumumab
agreement
janssen
biotech
treatment
certain
multiple
myeloma
indications
territories
including
europe
japan
subcutaneous
ofatumumab
agreement
novartis
ag
treatment
adults
relapsing
forms
multiple
sclerosis
teprotumumab
agreement
roche
granting
sublicense
horizon
therapeutics
plc
treatment
thyroid
eye
disease
subcutaneous
formulation
daratumumab
known
darzalex
daratumumab
approved
europe
treatment
adult
patients
certain
multiple
myeloma
indications
first
approved
genmab
created
therapy
ofatumumab
agreement
novartis
ag
approved
treatment
certain
chronic
lymphocytic
leukemia
indications
available
japan
also
available
territories
via
compassionate
use
oncology
access
programs
daratumumab
clinical
development
janssen
treatment
additional
multiple
myeloma
indications
blood
cancers
amyloidosis
genmab
also
broad
clinical
product
pipeline
genmab
technology
base
consists
validated
proprietary
next
generation
antibody
technologies
platform
generation
bispecific
antibodies
platform
creates
effector
function
enhanced
antibodies
platform
combines
two
acting
hexabody
molecules
introduce
selectivity
maximizing
therapeutic
potency
platform
enhances
potential
potency
bispecific
antibodies
hexamerization
company
intends
leverage
technologies
create
opportunities
full
future
products
genmab
alliances
top
tier
pharmaceutical
biotechnology
companies
genmab
headquartered
copenhagen
denmark
sites
utrecht
netherlands
princeton
new
jersey
tokyo
japan
adc
therapeutics
adc
therapeutics
sa
nyse
adct
late
biotechnology
company
pioneering
development
commercialization
highly
potent
targeted
antibody
drug
conjugates
adcs
patients
hematological
malignancies
solid
tumors
company
develops
adcs
applying
decades
experience
field
using
pyrrolobenzodiazepine
pbd
technology
adc
therapeutics
proprietary
rights
targets
strategic
target
selection
adcs
substantial
investment
early
clinical
development
enabled
adc
therapeutics
build
deep
clinical
research
pipeline
therapies
treatment
hematological
solid
tumor
cancers
company
multiple
adcs
ongoing
clinical
trials
ranging
first
human
confirmatory
phase
clinical
trials
usa
europe
numerous
preclinical
adcs
development
loncastuximab
tesirine
lonca
formerly
company
lead
product
candidate
evaluated
pivotal
phase
clinical
trial
treatment
relapsed
refractory
diffuse
large
lymphoma
dlbcl
showed
overall
response
rate
orr
exceeded
target
primary
endpoint
september
adc
therapeutics
submitted
biologics
license
application
food
drug
administration
seeking
accelerated
approval
lonca
treatment
patients
relapsed
refractory
dlbcl
camidanlumab
tesirine
cami
formerly
company
second
lead
product
candidate
evaluated
pivotal
phase
clinical
trial
treatment
relapsed
refractory
hodgkin
lymphoma
hl
shown
phase
clinical
trial
orr
hl
patients
dose
selected
phase
company
also
evaluating
cami
novel
approach
treatment
various
advanced
solid
tumors
adc
therapeutics
based
lausanne
biopôle
switzerland
operations
london
san
francisco
bay
area
new
jersey
information
please
visit
https
follow
company
twitter
linkedin
genmab
contacts
media
relations
marisol
peron
corporate
vice
president
communications
investor
relations
e
mmp
investor
relations
andrew
carlsen
senior
director
investor
relations
e
acn
adc
therapeutics
contacts
investors
amanda
hamilton
adc
therapeutics
tel
eu
media
alexandre
müller
dynamics
group
amu
tel
usa
media
annie
starr
degrees
astarr
tel
statements
genmab
media
release
contains
forward
looking
statements
words
believe
expect
anticipate
intend
plan
similar
expressions
identify
forward
looking
statements
actual
results
performance
may
differ
materially
future
results
performance
expressed
implied
statements
important
factors
could
cause
actual
results
performance
differ
materially
include
among
others
risks
associated
clinical
development
products
uncertainties
related
outcome
conduct
clinical
trials
including
unforeseen
safety
issues
uncertainties
related
product
manufacturing
lack
market
acceptance
products
inability
manage
growth
competitive
environment
relation
business
area
markets
inability
attract
retain
suitably
qualified
personnel
unenforceability
lack
protection
patents
proprietary
rights
relationships
affiliated
entities
changes
developments
technology
may
render
products
technologies
obsolete
factors
discussion
risks
please
refer
risk
management
sections
genmab
recent
financial
reports
available
risk
factors
included
genmab
recent
annual
report
form
filings
securities
exchange
commission
sec
available
genmab
undertake
obligation
update
revise
forward
looking
statements
media
release
confirm
statements
reflect
subsequent
events
circumstances
date
made
relation
actual
results
unless
required
law
genmab
subsidiaries
following
trademarks
genmab
genmab
combination
genmab
duobody
combination
duobody
hexabody
combination
hexabody
trademarks
novartis
ag
affiliates
darzalex
trademarks
janssen
pharmaceutica
nv
trademark
horizon
therapeutics
plc
statements
adc
therapeutics
press
release
contains
statements
constitute
statements
statements
statements
historical
facts
contained
press
release
including
statements
regarding
future
results
operations
financial
position
business
strategy
product
candidates
research
pipeline
ongoing
planned
preclinical
studies
clinical
trials
regulatory
submissions
approvals
addressable
patient
population
research
development
costs
timing
likelihood
success
well
plans
objectives
management
future
operations
statements
statements
based
management
beliefs
assumptions
information
currently
available
management
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
due
various
factors
including
described
filings
securities
exchange
commission
assurance
given
future
results
achieved
statements
contained
document
speak
date
press
release
expressly
disclaim
obligation
undertaking
update
statements
contained
press
release
reflect
change
expectations
change
events
conditions
circumstances
statements
based
unless
required
applicable
law
representations
warranties
expressed
implied
made
accuracy
statements
media
release
cvr
lei
code
genmab
kalvebod
brygge
copenhagen
v
denmark
attachment
